Drug therapy of chronic myeloid leukemia
Drug therapy of chronic myeloid leukemia
STANDARD TREATMENT: According to the evidence-based guidelines for the therapy of chronic myelogenous leukemia (CML) the combination of interferon alpha (IFN) and hydroxyurea with or without low dose ara-C is the standard treatment for chronic phase CML, if no allogeneic stem cell transplantation is requested. STI571: In cases of IFN failure the new tyrosine kinase inhibitor STI571 (Glivec) shows high response rates. STI571 specifically inhibits the BCR-ABL fusion protein which is pathogenetically relevant for CML and shows abnormal tyrosine kinase activity. 91% of all CML patients in chronic phase achieve a hematologic remission within 11 months and 55% cytogenetic remission. In blast crisis, 29% achieve hematologic remission which may be durable. CONCLUSION: The available data represent response rates. Until survival data are available, the evidence-based recommendations will remain valid.
7 -15
Hochhaus, A.
4c0b9da4-adfa-4253-8af7-78cec9e9a24f
Berger, U.
440811e1-e1c2-4f54-a435-b6dd61853857
Reiter, A.
8fc082eb-6b46-4412-86b2-f4c7669f0650
Lahaye, T.
97333448-5919-4fa2-b1d7-d4bcc51733f3
Kreil, S.
2404ac13-cdaa-43a3-913b-adceb79e598f
Hehlmann, R.
753d719b-7bf8-4f74-bfdc-6d5d47e5d2c7
2002
Hochhaus, A.
4c0b9da4-adfa-4253-8af7-78cec9e9a24f
Berger, U.
440811e1-e1c2-4f54-a435-b6dd61853857
Reiter, A.
8fc082eb-6b46-4412-86b2-f4c7669f0650
Lahaye, T.
97333448-5919-4fa2-b1d7-d4bcc51733f3
Kreil, S.
2404ac13-cdaa-43a3-913b-adceb79e598f
Hehlmann, R.
753d719b-7bf8-4f74-bfdc-6d5d47e5d2c7
Hochhaus, A., Berger, U., Reiter, A., Lahaye, T., Kreil, S. and Hehlmann, R.
(2002)
Drug therapy of chronic myeloid leukemia.
Medizinische Klinik, 97 (Supplement 1), .
Abstract
STANDARD TREATMENT: According to the evidence-based guidelines for the therapy of chronic myelogenous leukemia (CML) the combination of interferon alpha (IFN) and hydroxyurea with or without low dose ara-C is the standard treatment for chronic phase CML, if no allogeneic stem cell transplantation is requested. STI571: In cases of IFN failure the new tyrosine kinase inhibitor STI571 (Glivec) shows high response rates. STI571 specifically inhibits the BCR-ABL fusion protein which is pathogenetically relevant for CML and shows abnormal tyrosine kinase activity. 91% of all CML patients in chronic phase achieve a hematologic remission within 11 months and 55% cytogenetic remission. In blast crisis, 29% achieve hematologic remission which may be durable. CONCLUSION: The available data represent response rates. Until survival data are available, the evidence-based recommendations will remain valid.
This record has no associated files available for download.
More information
Published date: 2002
Identifiers
Local EPrints ID: 24752
URI: http://eprints.soton.ac.uk/id/eprint/24752
ISSN: 0723-5003
PURE UUID: 7f2c9a3e-8188-4ade-89fc-ddfd966082a8
Catalogue record
Date deposited: 06 Apr 2006
Last modified: 08 Jan 2022 06:49
Export record
Contributors
Author:
A. Hochhaus
Author:
U. Berger
Author:
A. Reiter
Author:
T. Lahaye
Author:
S. Kreil
Author:
R. Hehlmann
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics